Shamburg News · 8-K filed Nov 6, 2026, 3:17 PM EST
Braveheart Bio and Hengrui Present 52-Week HRS/BHB-1893 Extension Data in Obstructive HCM
BRVE · Braveheart Bio, Inc.
- Other event
- Reg FD disclosure
- Materiality: medium
On November 6, 2026, Braveheart Bio furnished a press release announcing data from the 52-week open-label extension of the Phase 2 study of HRS/BHB-1893 in obstructive hypertrophic cardiomyopathy, presented at the American Heart Association Scientific Sessions 2026. At Week 52, peak oxygen uptake increased by a mean of 2.7 mL/kg/min and 79% (33/42) of patients achieved a Valsalva LVOT gradient below 30 mmHg. The release also reported post hoc diastolic function data in non-obstructive HCM and an investor event scheduled for the same day.
Source: SEC EDGAR, Form 8-K, Items 7.01, 9.01, accession 0001628280-26-071586.
Written from the filing by Shamburg Markets. Figures are as reported by the company.